Anti-rabies monoclonal antibody (Rabimabs) - Zydus Cadila

Drug Profile

Anti-rabies monoclonal antibody (Rabimabs) - Zydus Cadila

Alternative Names: Anti-rabies monoclonal antibody - Zydus Cadila; Anti-rabies monoclonal antibody cocktail - Zydus Cadila; M777-16-3/MAb 62-71-3; MAB 5; Rabies mAb - Zydus Cadila/WHO; Rabimabs

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Zydus Cadila
  • Developer World Health Organization; Zydus Cadila
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Rabies

Most Recent Events

  • 21 Mar 2016 Cadila completes a phase I/II trial in Rabies in India (IM) (CTRI 2015-06-005838)
  • 21 Jan 2016 Phase-I/II clinical trials in Rabies in India (IM) (CTRI2015-06-005838)
  • 09 Oct 2015 Phase-I/II development is ongoing in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top